Literature DB >> 28486697

Evolution and dissemination of the Klebsiella pneumoniae clonal group 258 throughout Israeli post-acute care hospitals, 2008-13.

Amos Adler1,2, Ziv Lifshitz3, Michal Gordon4, Debbie Ben-David3, Efrat Khabra3, Samira Masarwa3, Orit Zion5, Mitchell J Schwaber2,3, Yehuda Carmeli2,3.   

Abstract

Objectives: The KPC-producing Klebsiella pneumoniae (KPC-KP) clonal group (CG) 258 has disseminated throughout Israeli post-acute care hospitals (PACHs). The objectives of the study were (i) to describe the evolution and (ii) to understand the dissemination modes of CG 258 in the PACH system in Israel.
Methods: KPC-KP surveillance cultures isolates were collected in Israeli PACHs in three national point-prevalence surveys: 2008, 2011 and 2013. CG 258 was identified by pilv-l PCR. WGS was performed for CG 258 isolates from 9 of 14 PACHs and data extracted for core-genome MLST (cgMLST) and for capsule polysaccharide gene cluster analysis.
Results: The proportional representation of CG 258 among the KPC-KP isolates increased from 72 of 104 isolates (69.2%) in 2008 to 113 of 133 isolates (85%) in 2011 ( P  =   0.004 for 2008 versus 2011) and remained high in 2013 [56 of 67 isolates (83.6%)]. All isolates were related to CG 258 clade 2. cgMLST phylogenetic analysis showed relative convergence in the 2008 survey, with increasing diversification in the subsequent surveys. A predominantly institutional dissemination pattern was observed only in centre F from southern Israel. A predominantly regional dissemination pattern was observed in the two PACHs in Jerusalem. The other PACHs were characterized by a combined institutional and generalized pattern, with the majority of isolates clustering within the same PACH and survey. Conclusions: CG 258 clade 2 has retained its predominance despite increased diversification. Although interchanging of CG 258 strains occurred between most PACHs, local spread is the leading cause of its dissemination.
© The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Year:  2017        PMID: 28486697     DOI: 10.1093/jac/dkx135

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  5 in total

1.  Molecular Epidemiology of Myroides odoratimimus in Nosocomial Catheter-Related Infection at a General Hospital in China.

Authors:  Shuang Yang; Qian Liu; Zhen Shen; Hua Wang; Lei He
Journal:  Infect Drug Resist       Date:  2020-06-25       Impact factor: 4.003

2.  Widespread emergence of OmpK36 loop 3 insertions among multidrug-resistant clones of Klebsiella pneumoniae.

Authors:  Sophia David; Joshua L C Wong; Julia Sanchez-Garrido; Hok-Sau Kwong; Wen Wen Low; Fabio Morecchiato; Tommaso Giani; Gian Maria Rossolini; Stephen J Brett; Abigail Clements; Konstantinos Beis; David M Aanensen; Gad Frankel
Journal:  PLoS Pathog       Date:  2022-07-11       Impact factor: 7.464

3.  Recurrent emergence of Klebsiella pneumoniae carbapenem resistance mediated by an inhibitory ompK36 mRNA secondary structure.

Authors:  Joshua L C Wong; Sophia David; Julia Sanchez-Garrido; Jia Z Woo; Wen Wen Low; Fabio Morecchiato; Tommaso Giani; Gian Maria Rossolini; Konstantinos Beis; Stephen J Brett; Abigail Clements; David M Aanensen; Silvi Rouskin; Gad Frankel
Journal:  Proc Natl Acad Sci U S A       Date:  2022-09-12       Impact factor: 12.779

Review 4.  The Infinity War: How to Cope with Carbapenem-resistant Enterobacteriaceae.

Authors:  Jin-Hong Yoo
Journal:  J Korean Med Sci       Date:  2018-09-03       Impact factor: 2.153

5.  Comparison of core-genome MLST, coreSNP and PFGE methods for Klebsiella pneumoniae cluster analysis.

Authors:  Floriana Gona; Francesco Comandatore; Simone Battaglia; Aurora Piazza; Alberto Trovato; Giovanni Lorenzin; Paola Cichero; Anna Biancardi; Paola Nizzero; Matteo Moro; Daniela Maria Cirillo
Journal:  Microb Genom       Date:  2020-03-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.